Tealwood Asset Management Inc. Has $1.66 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Tealwood Asset Management Inc. reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) by 2.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,008 shares of the company’s stock after selling 247 shares during the period. Tealwood Asset Management Inc.’s holdings in Neurocrine Biosciences were worth $1,656,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mather Group LLC. acquired a new stake in Neurocrine Biosciences in the 1st quarter valued at $26,000. Headinvest LLC acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter worth about $28,000. Lindbrook Capital LLC increased its stake in shares of Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after purchasing an additional 96 shares during the last quarter. EdgeRock Capital LLC acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $31,000. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $33,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NBIX has been the topic of several recent analyst reports. Barclays boosted their price objective on shares of Neurocrine Biosciences from $150.00 to $169.00 and gave the stock an “overweight” rating in a research note on Thursday, May 2nd. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday. Canaccord Genuity Group boosted their price objective on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. BMO Capital Markets upped their price target on shares of Neurocrine Biosciences from $129.00 to $138.00 and gave the company a “market perform” rating in a research note on Thursday, May 2nd. Finally, Citigroup upped their price target on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Six investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $152.00.

Read Our Latest Report on NBIX

Insider Activity at Neurocrine Biosciences

In related news, CFO Matt Abernethy sold 15,000 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $140.24, for a total value of $2,103,600.00. Following the completion of the transaction, the chief financial officer now owns 31,528 shares of the company’s stock, valued at approximately $4,421,486.72. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Eric Benevich sold 19,818 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the completion of the transaction, the insider now owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Matt Abernethy sold 15,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $140.24, for a total transaction of $2,103,600.00. Following the transaction, the chief financial officer now directly owns 31,528 shares of the company’s stock, valued at approximately $4,421,486.72. The disclosure for this sale can be found here. Insiders sold a total of 88,697 shares of company stock valued at $11,975,615 in the last quarter. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock traded up $0.50 on Friday, reaching $134.57. 2,204,933 shares of the stock were exchanged, compared to its average volume of 716,229. The firm’s 50 day moving average is $137.06 and its 200-day moving average is $135.05. Neurocrine Biosciences, Inc. has a one year low of $93.02 and a one year high of $148.37. The firm has a market cap of $13.54 billion, a PE ratio of 37.07 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). The firm had revenue of $515.30 million for the quarter, compared to the consensus estimate of $512.21 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. On average, equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current fiscal year.

About Neurocrine Biosciences

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Featured Articles

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.